Equities research analysts predict that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will post sales of $7.32 million for the current quarter, Zacks Investment Research reports. Three analysts have made estimates for Pieris Pharmaceuticals’ earnings, with the highest sales estimate coming in at $9.01 million and the lowest estimate coming in at $5.10 million. Pieris Pharmaceuticals posted sales of $11.69 million during the same quarter last year, which would indicate a negative year over year growth rate of 37.4%. The firm is expected to report its next quarterly earnings report on Thursday, August 8th.
On average, analysts expect that Pieris Pharmaceuticals will report full year sales of $30.24 million for the current fiscal year, with estimates ranging from $20.40 million to $35.58 million. For the next year, analysts forecast that the firm will post sales of $25.46 million, with estimates ranging from $13.33 million to $34.10 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Pieris Pharmaceuticals.
Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its quarterly earnings data on Friday, May 10th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.18) by ($0.02). Pieris Pharmaceuticals had a negative return on equity of 64.64% and a negative net margin of 84.75%. The company had revenue of $8.55 million during the quarter, compared to analyst estimates of $7.85 million.
Shares of PIRS stock opened at $4.70 on Friday. The business has a 50 day moving average of $4.13. Pieris Pharmaceuticals has a one year low of $2.39 and a one year high of $6.55. The firm has a market cap of $217.73 million, a price-to-earnings ratio of -9.40 and a beta of 1.22.
A number of institutional investors have recently modified their holdings of PIRS. BNP Paribas Arbitrage SA acquired a new stake in shares of Pieris Pharmaceuticals in the 1st quarter worth $36,000. SG Americas Securities LLC acquired a new position in Pieris Pharmaceuticals during the fourth quarter worth about $36,000. Prudential Financial Inc. acquired a new position in Pieris Pharmaceuticals during the fourth quarter worth about $43,000. Alambic Investment Management L.P. acquired a new position in Pieris Pharmaceuticals during the fourth quarter worth about $59,000. Finally, D. E. Shaw & Co. Inc. raised its position in Pieris Pharmaceuticals by 107.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 49,904 shares of the biotechnology company’s stock worth $133,000 after acquiring an additional 25,794 shares during the last quarter. 59.70% of the stock is currently owned by institutional investors.
About Pieris Pharmaceuticals
Pieris Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers and develops anticalin-based drugs in the United States. The company develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins found in blood plasma and other bodily fluids.
Read More: What are Closed-End Mutual Funds?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.